We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics (HAE) Gets FDA Clearance for NexSys PCS Upgrades
Read MoreHide Full Article
Haemonetics (HAE - Free Report) recently received FDA clearance for the enhancements to its NexSys PCS plasma collection system. These include a new plasma collection bowl, which features a design that optimizes performance and new Express Plus Technology engineered to reduce procedure time.
With the latest advancements, Haemonetics expects an average procedure time of 33 to 38 minutes using the standard FDA nomogram. This will help customers achieve new levels of plasma center efficiency and lower costs to collect.
About NexSys PCS
NexSys PCS is the industry's most advanced, completely integrated system designed to streamline plasma collections and improve yield, productivity, safety, quality, compliance and donor satisfaction. The bi-directionally connected NexSys PCS with NexLynk DMS donor management software already delivers a 16-minute average reduction in donor door-to-door time, with a significant portion of this improvement occurring before and post-procedure.
Image Source: Zacks Investment Research
In addition, NexSys PCS with Persona Technology safely delivers, on average, a 9% to 12% additional plasma yield by personalizing each collection to individual donor characteristics.
More on the News
Within the plasma collection market, Haemonetics carries nearly five decades of industry experience and more than 50 million real-world collections to date on NexSys PCS. The company plans to have an initial market release of NexSys PCS with the new bowl and Express Plus Technology in the next coming months.
Per the company’s management, advancing these innovations ultimately leads the industry in reducing the cost per liter for collectors and ensuring the best experience for their donors.
Industry Prospects
Per a Research report, the global plasma fractionation market was valued at $26.5 billion in 2022 and is expected to witness a CAGR of 6.5% by 2027.
Recent Highlights
Earlier in March 2023, Haemonetics received FDA’s 510(k) clearance on the next-generation software for the Cell Saver Elite+ Autotransfusion System. This software upgrade named Intelligent Control, offers customers key enhancements to help simplify operations, supporting enhanced efficiency and an improved user experience.
Meanwhile, HAE posted better-than-expected earnings and revenues in the fourth quarter of fiscal 2023. The company’s Plasma business is a powerful value driver fueled by strong end-market demand. Revenues from this franchise improved 31% in the fourth quarter, driven by volume growth and price benefits.
The Hospital business unit delivered its first $100 million revenues in the last reported quarter. This was primarily driven by growth in Vascular Closure and Hemastosis Management.
Price Performance
In the past six months, Haemonetics has outperformed the industry. Shares of the company have rallied 7.8% compared with the industry’s rise of 5.9%.
Zacks Rank and Key Picks
Haemonetics currently sports a Zacks Rank #1 (Strong Buy).
Penumbra’s stock has surged 158% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 46.1% in the past year against the industry’s 22.8% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Rockwell Medical’s loss per share have narrowed from 58 cents to 48 cents for 2023 in the past 30 days. Shares of the company have surged 214.1% in the past year against the industry’s 22.8% decline.
RMTI’s earnings beat estimates in three of the trailing four quarters, the average surprise being 30.4%. In the last reported quarter, Rockwell Medical delivered an earnings surprise of 44.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Haemonetics (HAE) Gets FDA Clearance for NexSys PCS Upgrades
Haemonetics (HAE - Free Report) recently received FDA clearance for the enhancements to its NexSys PCS plasma collection system. These include a new plasma collection bowl, which features a design that optimizes performance and new Express Plus Technology engineered to reduce procedure time.
With the latest advancements, Haemonetics expects an average procedure time of 33 to 38 minutes using the standard FDA nomogram. This will help customers achieve new levels of plasma center efficiency and lower costs to collect.
About NexSys PCS
NexSys PCS is the industry's most advanced, completely integrated system designed to streamline plasma collections and improve yield, productivity, safety, quality, compliance and donor satisfaction. The bi-directionally connected NexSys PCS with NexLynk DMS donor management software already delivers a 16-minute average reduction in donor door-to-door time, with a significant portion of this improvement occurring before and post-procedure.
Image Source: Zacks Investment Research
In addition, NexSys PCS with Persona Technology safely delivers, on average, a 9% to 12% additional plasma yield by personalizing each collection to individual donor characteristics.
More on the News
Within the plasma collection market, Haemonetics carries nearly five decades of industry experience and more than 50 million real-world collections to date on NexSys PCS. The company plans to have an initial market release of NexSys PCS with the new bowl and Express Plus Technology in the next coming months.
Per the company’s management, advancing these innovations ultimately leads the industry in reducing the cost per liter for collectors and ensuring the best experience for their donors.
Industry Prospects
Per a Research report, the global plasma fractionation market was valued at $26.5 billion in 2022 and is expected to witness a CAGR of 6.5% by 2027.
Recent Highlights
Earlier in March 2023, Haemonetics received FDA’s 510(k) clearance on the next-generation software for the Cell Saver Elite+ Autotransfusion System. This software upgrade named Intelligent Control, offers customers key enhancements to help simplify operations, supporting enhanced efficiency and an improved user experience.
Meanwhile, HAE posted better-than-expected earnings and revenues in the fourth quarter of fiscal 2023. The company’s Plasma business is a powerful value driver fueled by strong end-market demand. Revenues from this franchise improved 31% in the fourth quarter, driven by volume growth and price benefits.
The Hospital business unit delivered its first $100 million revenues in the last reported quarter. This was primarily driven by growth in Vascular Closure and Hemastosis Management.
Price Performance
In the past six months, Haemonetics has outperformed the industry. Shares of the company have rallied 7.8% compared with the industry’s rise of 5.9%.
Zacks Rank and Key Picks
Haemonetics currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus (LNTH - Free Report) and Rockwell Medical (RMTI - Free Report) . While Penumbra and Lantheus each sport a Zacks Rank #1, Rockwell Medical carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has surged 158% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 46.1% in the past year against the industry’s 22.8% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Rockwell Medical’s loss per share have narrowed from 58 cents to 48 cents for 2023 in the past 30 days. Shares of the company have surged 214.1% in the past year against the industry’s 22.8% decline.
RMTI’s earnings beat estimates in three of the trailing four quarters, the average surprise being 30.4%. In the last reported quarter, Rockwell Medical delivered an earnings surprise of 44.4%.